For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 63,489 | |||
| General and administrative | 20,547 | |||
| Total operating expenses | 84,036 | |||
| Loss from operations | -84,036 | |||
| Interest income | 11,297 | |||
| Interest expense | 63 | |||
| Change in fair value of safe liabilities | 0 | |||
| Other expense | -119 | |||
| Total other income, net | 11,115 | |||
| Loss before income tax | -72,921 | |||
| Income tax expense | 1,230 | |||
| Net loss | -74,151 | |||
| Basic EPS | -4.05 | |||
| Diluted EPS | -4.05 | |||
| Basic Average Shares | 18,322,533 | |||
| Diluted Average Shares | 18,322,533 | |||
Tectonic Therapeutic, Inc. (TECX)
Tectonic Therapeutic, Inc. (TECX)